Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216952 · ClinicalTrials.gov registry record · Phase 2
Ulipristal Acetate for Use in Early Pregnancy Loss
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT05216952 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 3 participants.
The verdict
NCT05216952, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The investigators will study the feasibility of using 90mg ulipristal acetate, a selective progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical management of early pregnancy loss. Patients will be followed to assess effective treatment of early pregnancy loss, additional interventions needed, side effects, adverse events and patient acceptability.
Interventions
- DRUG Ulipristal Acetate Tablets
- DRUG Misoprostol Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2023-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05216952
The ClinicalTrials.gov registry entry for NCT05216952 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ulipristal Acetate Tablets is the first listed.
NCT05216952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05216952 about?
NCT05216952 is a clinical study titled "Ulipristal Acetate for Use in Early Pregnancy Loss". The investigators will study the feasibility of using 90mg ulipristal acetate, a selective progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical management of early pregnancy loss. Patients will be followed to assess effective treatment of early pregnancy loss, a...
What is the current status of trial NCT05216952?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-05-11. Estimated completion is 2023-04-30.
What interventions are being tested in trial NCT05216952?
The interventions under investigation include: Ulipristal Acetate Tablets (DRUG), Misoprostol Pill (DRUG).
Who is sponsoring clinical trial NCT05216952?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.